Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Depot NTX in Homeless Veterans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Homeless per the federal definition (HEARTH Act, 2009), which includes individuals who lack a fixed, regular, and adequate nighttime residence; and those who have a primary nighttime residence that is a supervised publicly or privately operated shelter designed to provide temporary accommodations (including welfare hotels, congregate shelters, and transitional housing); an institution that provides a temporary residence for individuals intended to be institutionalized; and/or a public or private place not designed for, or ordinarily used as, a regular sleeping accommodation for human beings (including doubled up with a friend or family member).~2. Meet criteria for a DSM-IV diagnosis of alcohol abuse or dependence in the past year.~3. Last reported drink between 12 hours and 12 months prior, and BAC by breathalyzer of .08 or less.~4. Age between 18 and 64 years.~5. Eligible to receive VA services.~6. Willing to provide informed consent that will include all study procedures.~7. Those who report any opiate use in the past month must pass a naloxone challenge test (no sign of opiate withdrawal after IM injection of 0.8 mg naloxone).~8. If female of childbearing potential -- must be using adequate contraception.~9. Cognitively intact and showing no signs of delusional thought processes on the Short Blessed test (Callahan, 2002) and SCID checklist. Those with an untreated SMI and/or not capable of understanding the study due to an active cognitive impairment or delusional thought process will be excluded.~10. Speak English sufficiently to understand instructions and assessments.~Exclusion Criteria:~1. Untreated disorder that might make participation hazardous (e.g. untreated psychosis or bipolar disorder with mania on SCID checklist or significant suicide risk on Modified Scale of Suicidal Ideation (MSSI).~2. Use of contraindicated medications such as an opioid for a documented diagnosis or opiate maintenance.~3. Chronic pain condition or expected procedure during the study that is likely to require opioid analgesia.~4. Contraindicated medical conditions including pregnancy/lactation; liver failure or liver function test levels greater than three times normal; glaucoma; prior adverse reaction to naltrexone; life expectancy of less than 6 months or medical condition that will likely require skilled nursing facility care) within 6 months.~5. Stated plan to leave the area within 6 months of enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- XR-NTX (Type: EXPERIMENTAL): Depot naltrexone (Vivitrol) 380 mg. IM monthly
- Oral Naltrexone (Type: ACTIVE_COMPARATOR): Naltrexone 50 mg tablet PO daily

Based on this trial design, predict the completion outcome and termination type (if applicable).